ClinicalTrials.gg
Not yet recruitingNCT07066735Updated Jul 17, 2025

Extracorporeal Shock-Wave Therapy (ESWT) vs Phytotherapy vs Combined in Treatment of Chronic Prostatitis

An interventional study of ESWT and Phytotherapy that contains powder extract of (saw palmetto , tomato , uva ursi , pygeum and pumpkin in Chronic Prostatitis (CP), sponsored by Ain Shams University. Not yet recruiting at 1 site in Egypt. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-17.

Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

to compare the efficacy and safety of ESWT combined with phytotherapy, ESWT alone and phytotherapy alone in treatment of chronic prostatitis.

Read the detailed description

In this study the investigators will conduct a Prospective randomized clinical trial, patients will be randomized to 3 groups where they will use use radial waves device (INTELECT RPW SHOCKWAVE) By Chattanooga for ESWT. Another group will receive Phytothyrapy that will be capsules containing powder extract of saw palmetto , tomato , uvaursi , pygeum and pumpkin. while the last group will receive both.

02

Conditions studied

  • Chronic Prostatitis (CP)

Browse trials for

Keywords

  • Chronic prostatitis
  • ESWT
  • Phytotherapy
  • LUTS
03

In context

Prostatitis

89 studies on the registry are indexed under Prostatitis; 12 are open to participants now.

This study's planned enrollment of 90 is above the median of 61 across 74 interventional studies indexed under Prostatitis.

Browse Prostatitis studies →

Lead sponsor

Ain Shams University is the lead sponsor of 1,958 studies on the registry; 432 are open to participants now.

Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Perineal or pelvic pain or discomfort of at least 3 months
  • NIH-CPSI total score greater than 15,
  • Negative semen cultures for bacteria.

Exclusion criteria

Exclusion Criteria:

  • Evidence of bacteria in seminal culture tests,
  • Urinary stones,
  • Uncontrolled coagulopathy,
  • Chronic bacterial prostatitis,
  • Bladder and prostate cancer,
  • Medications that could affect lower urinary tract function during the last month
  • Serum prostate-specific antigen levels (PSA) more than 4 ng/mL
  • History of prostate surgery or radiotherapy
  • Perineal anatomical abnormalities
  • Neurological abnormalities.
  • Previous extensive pelvic injuries
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Group A ESWT and Phytotherapy

    First group will undergo ( ESWT -Transperineal- once a week for 8 consecutive weeks with a protocol of 3000 pulses each; pressure: 1.8-2.0 bar and a frequency of 10 Hertz (Hz) (Zhang et al . 2018) combined with Phytotherapy that contains powder extract of (saw palmetto , tomato , uva ursi , pygeum , pumpkin ) 1capsule twice daily.

    Device: ESWT · Drug: Phytotherapy that contains powder extract of (saw palmetto , tomato , uva ursi , pygeum and pumpkin

  • Experimental
    Group B: ESWT alone

    Transperineal- once a week for 8 consecutive weeks with a protocol of 3000 pulses each; pressure: 1.8-2.0 bar and a frequency of 10 Hertz (Hz)

    Device: ESWT

  • Active comparator
    Group 3: Phytotherapy alone

    Phytotherapy that contains powder extract of (saw palmetto , tomato , uva ursi , pygeum , pumpkin ) 1capsule twice daily

    Drug: Phytotherapy that contains powder extract of (saw palmetto , tomato , uva ursi , pygeum and pumpkin

Interventions

  • DeviceESWT

    Transperineal Shockwaves that are applied once a week for 8 consecutive weeks with a protocol of 3000 pulses each; pressure: 1.8-2.0 bar and a frequency of 10 Hertz (Hz)

  • DrugPhytotherapy that contains powder extract of (saw palmetto , tomato , uva ursi , pygeum and pumpkin

    1capsule tob be taken twice daily for one month.

06

What researchers measure

Primary outcomes

  1. compare the degree of symptoms relief between the three groups

    using National Institutes of Health-developed Chronic Prostatitis Symptom Index (NIHCPSI) that will be filled by the patients pre and post intervention at 4 weeks and 8 weeks, 2 and 4 months. It comprises three key domains: pain (scored from 0 to 21), urinary symptoms (0 to 10), and the impact on quality of life (0 to 12), with a total score range spanning from 0 to 43. Higher scores reflect more severe symptoms and a worse overall outcome, while lower scores indicate milder symptoms and a better clinical picture. Severity is typically interpreted as mild (0-9), moderate (10-18), severe (19-31), and very severe (32-43), making the scale valuable for both diagnosis and monitoring treatment progress.

    Time frame: pre intervenon, at 4 and 8 weeks post intervention and at 2 and 4 months post intervention.

07

Study locations

1 site
08

References and documents

Publications

  • Wagenlehner FM, van Till JW, Magri V, Perletti G, Houbiers JG, Weidner W, Nickel JC. National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) symptom evaluation in multinational cohorts of patients with chronic prostatitis/chronic pelvic pain syndrome. Eur Urol. 2013 May;63(5):953-9. doi: 10.1016/j.eururo.2012.10.042. Epub 2012 Nov 2. PubMed 23141933 ↗
  • Sakr AM, Fawzi AM, Kamel M, Ali MM. Outcomes and clinical predictors of extracorporeal shock wave therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome: a prospective randomized double-blind placebo-controlled clinical trial. Prostate Cancer Prostatic Dis. 2022 Mar;25(1):93-99. doi: 10.1038/s41391-021-00464-8. Epub 2021 Oct 11. PubMed 34635804 ↗
  • Palmieri A, Cai T, Di Luise L, D'Alterio C, La Cava G, Cirigliano L, Di Giovanni A, Gallelli L, Capece M. Extracorporeal shock wave therapy in association with bromelain and escin for the management of patients affected by chronic prostatitis/chronic pelvic pain syndrome. Biomed Rep. 2022 Nov 25;18(1):7. doi: 10.3892/br.2022.1589. eCollection 2023 Jan. PubMed 36544851 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Feb 2026, 6 months later.

Of 21 interventional studies with no phase under Prostatitis, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 25. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2025
First posted
Jul 15, 2025
StartEst.
Jul 20, 2025
Primary completionEst.
Feb 1, 2026
CompletionEst.
Mar 1, 2026
Last update
Jul 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07066735
Responsible party
Younan Ramsis (Lecturer of Urology, Ain Shams University) — Principal investigator
First posted
Jul 15, 2025
Start date
Jul 20, 2025 (estimated)
Primary completion
Feb 1, 2026 (estimated)
Completion
Mar 1, 2026 (estimated)
Last update
Jul 17, 2025

Study contacts

Younan R. Samir, lecturer
Contact
dr_yona@live.com
00201201255511
Walid E. Mousa, Assisstant Professor
Contact
waleedmousa2@yahoo.com
00201067628771
Mohammed Y. Yassin, Professor
study chair · Ain Shams University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion